Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastric mucosal proteins at ulcerated or damaged sites refer to the proteinaceous exudate, primarily consisting of albumin, fibrinogen, and globulins, that becomes exposed when the gastric lining is breached (StatPearls, NBK551527). In the acidic environment of the stomach, these proteins carry a strong positive charge, making them a unique pharmacological target for cytoprotective agents (PubChem, CID 6398). Drugs like sucralfate undergo polymerization to form a negatively charged, paste-like substance that selectively binds to these exposed proteins (PubMed, 2671365). This interaction creates a physical barrier that shields the damaged tissue from further injury by gastric acid, pepsin, and bile salts, thereby facilitating the natural healing process (NIH, LiverTox). This target is central to the treatment of peptic ulcer disease and various forms of gastritis where mucosal integrity is compromised.
Formation of a physical barrier by binding to positively charged proteins (such as albumin and fibrinogen) at the site of mucosal damage, protecting the ulcer from gastric acid, pepsin, and bile salts (StatPearls, NBK551527).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastric mucosal proteins at ulcerated sites.